Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.67 |
| ▸ | PLAU | P00749 | 2/20 | 0.65 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | F10 | P00742 | 1/20 | 0.65 |
| ▸ | PLAT | P00750 | 1/20 | 0.65 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.65 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.65 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | F12 | P00748 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343477 | 1.00 | TMPRSS4 (0.67) | TMPRSS4PLAUF2F10PLAT | |
| Dibromsalan SCHEMBL29211119 | 0.97 | PLAU (0.66) | TMPRSS4PLAUF2F10PLAT | |
| Dibromsalan SCHEMBL29496335 | 0.90 | PLAU (0.73) | TMPRSS4PLAUF2F10PLAT | |
| Dibromsalan SCHEMBL646973 | 0.90 | PLAU (0.73) | TMPRSS4PLAUF2F10PLAT | |
| SCHEMBL9967909 | 0.85 | HSPD1 (0.67) | HSPD1HSPE1P2RX1MEN1KMT2A | |
| Bromochlorosalicylanilide SCHEMBL152257 | 0.84 | P2RX1 (0.77) | TMPRSS4PLAUF2F10PLAT | |
| SCHEMBL23825504 | 0.83 | SORT1 (0.74) | HSPD1HSPE1F12CYP2C9 | |
| SCHEMBL29980628 | 0.83 | SORT1 (0.74) | HSPD1HSPE1F12CYP2C9 | |
| SCHEMBL330366 | 0.83 | P2RX1 (0.78) | TMPRSS4HSPD1HSPE1P2RX1 | |
| SCHEMBL10967705 | 0.83 | MEN1 (0.64) | PLAUF2F10PLATHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| EP-3653303-B1 | PIPETTE TIP RACK | BIOTIX INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250026741-A1 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-01-23 | — | — | US | disclosed |
| US-12201987-B2 | Pipette tip rack | BIOTIX, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4376673-B1 | FILAMENTS FOR ORAL CARE IMPLEMENTS | UNILEVER IP HOLDINGS B V (NL) | 2025-01-01 | — | — | EP | disclosed |
| CN-118042960-A | Filaments for oral care implements | 联合利华知识产权控股有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11590490-B2 | Pipette tips | BIOTIX, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2023006359-A1 | FILAMENTS FOR ORAL CARE IMPLEMENTS | UNILEVER IP HOLDINGS B.V. (NL) | 2023-02-02 | — | — | WO | disclosed |
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2021-12-23 | — | — | US | disclosed |
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2021-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20030176530-A1 | Antimicrobial contact lens case | LINDLEY KAREN FRANCES (US) | 2003-09-18 | — | — | US | disclosed |
| WO-2003049776-A1 | ANTIMICROBIAL CONTACT LENS CASE | NOVARTIS AG (CH) | 2003-06-19 | — | — | WO | disclosed |
| US-20030108761-A1 | Anti-bacterial paper products | EDDLEMON TAMMY (US) | 2003-06-12 | — | — | US | disclosed |
| WO-2001070189-A1 | METHOD AND COMPOSITION FOR SKIN LIGHTENING APPLYING CARBOXYLIC ACIDS | UNILEVER PLC (GB) | 2001-09-27 | — | — | WO | disclosed |
| US-6138315-A | Antimicrobial active compounds | CHESEBROUGH-POND'S USA CO., DIVISON OF CONOPCO, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1999035911-A1 | ANTIMICROBIAL TOOTHBRUSH | UNILEVER PLC (GB) | 1999-07-22 | — | — | WO | disclosed |
| US-5919152-A | Antibacterial swabs | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| US-5846215-A | Antibacterial swabs | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| US-4022880-A | ZINC IONS, 3,4,5-TRIBROMO-SALICYLANILIDE, QUATERNARY AMMONIUM COMPOUNDS | LEVER BROTHERS COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSP90AB1, HSP90AB2P | TMPRSS4 3982/4885PLAU 2952/4885F2 4686/4885 |
| US-20250026741-A1 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | PTPN18, PTPN7, PTPN1 | TMPRSS4 2060/4885PLAU 3807/4885F2 4871/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | TMPRSS4 3361/4885PLAU 1363/4885F2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.